Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial. (31st December 2021)

• Record Type: Journal Article
• Authors: Joseph‐Mathurin, Nelly; Llibre‐Guerra, Jorge J; McCullough, Austin A.; Li, Yan; Hofmann, Carsten; Wojtowicz, Jakub; Wang, Qing; Wang, Guoqiao; Gordon, Brian A.; Chen, Charles D.; Brooks, William S.; Gauthier, Serge; Holdridge, Karen C.; Hsiung, Ging‐Yuek Robin; Jack, Clifford R.; Klein, Gregory; Masellis, Mario; Mummery, Catherine J.; Preboske, Gregory M.; Santacruz, Anna; Wallon, David; Xiong, Chengjie; Yaari, Roy; McDade, Eric; Bateman, Randall J.; Salloway, Stephen P.; Benzinger, Tammie L.S.; Clifford, David B.
• Is Part Of: Alzheimer's & dementia. Volume 17:(2021)Supplement 1
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-31
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.056393
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Amyloid‐related imaging abnormalities (ARIA), edema (E) or hemorrhagic (H) type, have been reported in trials of anti‐β‐amyloid passive immunotherapies in sporadic and dominantly inherited Alzheimer Disease (DIAD). However, beyond APOE‐ɛ4 the risk factors and clinical implications of ARIA are not well understood, especially in DIAD populations. Here we characterize ARIA, focusing on ARIA‐E in the DIAN‐TU‐001 trial evaluating gantenerumab and solanezumab in DIAD. Method: The DIAN‐TU‐001 trial enrolled 194 participants, including 144 DIAD mutation‐carriers receiving gantenerumab (n=52), solanezumab (n=52), or a placebo (n=40). Clinical assessments included the Clinical Dementia Rating (CDR). Imaging assessments included PiB‐PET and safety MR, including T2‐FLAIR and T2*‐GRE. Treatment dosage and APOE‐ɛ4 status were also reported. Result: Eleven participants developed a total of 14 ARIA‐E episodes (discovered on scheduled safety MR) and three had associated mild symptoms reported in retrospect ( e.g . headache, imbalance disorder). Though one ARIA‐E case was observed in the solanezumab arm, the following results focus on the gantenerumab arm to prevent unblinding. Recipients of gantenerumab were more likely to develop ARIA‐E compared to placebo (odds ratio (OR)=9.29, 95% confidence interval (CI)=[1.1, 75.9], p ‐value<0.05). ARIA‐E participants were PiB‐PET+ and 60% were CDR>0. APOE‐ɛ4 tends to be associated with risk for developing ARIA‐E (OR=5.0, 95%CI=[1.0, 30.4], p ‐value=0.055). ARIA‐E were not observed at initial 225mg dose and were first observed after a titration step (within 4‐24 weeks, after 1‐6 injections, Table 1). Time‐to‐resolution of ARIA‐E was 10.4±6.2weeks. Seven of ten ARIA‐E patients paused/reduced dose escalation and three discontinued treatment. Overall, developing ARIA‐E did not increase the odds of trial discontinuation (OR=1.57, 95%CI=[0.34, 7.33], p ‐value=0.57). ARIA‐E occurred primarily in the occipital lobe (71%) with associated incident ARIA‐H (microhemorrhages or superficial siderosis) in 60% of ARIA‐E participants. ARIA‐E size was associated with microhemorrhage count (Spearman's rho=0.72, p ‐value<0.05), rate of change (rho=0.78, p ‐value<0.01), and baseline PiB‐PET (rho=0.68, p ‐value<0.05). Normalizing by baseline, PiB‐PET decreased similarly in ARIA‐E+ (‐0.21±0.20) and ARIA‐E‐ (‐0.16±0.20) participants. Conclusion: In DIAD, gantenerumab dose over 225mg increased ARIA‐E risk, possibly more for APOE‐ɛ4 carriers. ARIA‐E was reversible, generally asymptomatic, and without increased odds of trial discontinuation. These aspects of drug response give insights for managing ARIA‐E occurrence in future trials.